ARTICLE | Company News
EC approves Imbruvica for CLL, MCL
October 18, 2014 2:34 AM UTC
The European Commission has approved Imbruvica ibrutinib from Pharmacyclics Inc. (NASDAQ:PCYC) and the Janssen-Cilag International NV unit of Johnson & Johnson (NYSE:JNJ) to treat patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
The European approval triggers a milestone payment of undisclosed size to Pharmacyclics from J&J. The biotech received $60 million in milestones when FDA approved the drug for MCL in November 2013 and for CLL in July 2014. ...